The Dupont Merck Pharmaceutical Company

Bristol-myers Squibb Pharma Company

Dupont Pharmaceuticals Company

Endo Pharmaceuticals Inc.

Dupont Pharmaceuticals, Inc.

Gary Avonn Cain

Sang W Tam

Paul J Gilligan

Richard Eric Olson

Shaker Ahmed Mousa

Chu-Biao Xue

Douglas G Batt

John Wityak

Robert J Chorvat

Paul Joseph Gilligan

Rajagopal Bakthavatchalam

John Francis McElroy

Donald J Pinto

Argyrios Georgios Arvanitis

James Peter Beck

Munir A Hussain

William Frank Degrado

Charles Joseph Eyermann

Thais Motria Sielecki-Dzurdz

Thomas E Christos

Christopher A Teleha

Spencer Drummond, Jr

Denette K Murphy

Reginald O Cann

The present invention relates to compounds having pharmacological activity toward the 5-HT receptor. Pharmaceutical compositions and methods for their use in the treatment of CNS disorders are described.

5-HT7 receptor antagonists

Arylamino fused pyridines

This invention pertains to novel salt forms of trophenylethylene compound, such as 3-&lsqb;4(1,2-diphenyl-but-1-enyl)-phenyl&rsqb;-acrylic acid, as selective estrogen receptor modulators. This invention also provides methods for the treatment and/or prevention of breast, uterine, ovarian, prostrate and colon cancer, osteoporosis, cardiovascular disease, and benign proliferative disorders, as well as pharmaceutical compositions of the compounds of the present invention.

Specific salt forms of triphenylethylene derivatives as selective estrogen receptor modulators

The present invention relates to compounds having pharmacological activity toward the 5-HT,receptor. Pharmaceutical compositions and methods for their use in the treatment of CNS disorders are described.

The present invention pertains to a process for the preparation of the 10-keto analogs of morphinan compounds. In the case of compounds having a 3-hydroxyl group, the 3-methyl ether protected analog is synthesized by selective phenolic methylation in the presence of the basic amino group. When nalbuphine, morphine, or codeine is used as the starting material, the additional 6-hydroxyl group is protected using acetylation. The protected analog is selectively oxidized by treatment with cerium ammonium nitrate to provide the 10-(S)-hydroxy adduct. The 10-(S)-hydroxy adduct is further oxidized to the 10-keto analog. Any protecting groups that were added prior to oxidation are cleaved subsequent to oxidation to form the desired 10-ketomorphinan.

Sequential benzylic oxidations of the naloxone ring system

This invention relates to novel isoxazolines and isoxazoles which are useful as antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex or the vitronectin receptor, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.

Isoxazoline and isoxazole fibrogen receptor antagonists

Corticotropin releasing factor (CRF) antagonists of formula I or formula II: ##STR1## and their use in treating anxiety, depression, and other psychiatric and neurological disorders.

Arylamino fused pyrimidines

Isoxazoline and isoxazole fibrinogen receptor antagonists

This invention relates to novel compounds containing basic and acidic termini, pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.

Aromatic compounds containing basic and acidic termini useful as

Novel unsaturated ether derivatives of alkyl piperidine and pyrrolidine compounds, pharmaceutical compositions containing them, methods of preparation and methods of using these compounds as antipsychotic agents are disclosed.

Ether derivatives of alkyl piperidines and pyrrolidines as antipsychotic

There are provided cycloalkyl piperidine compounds which are useful in the treatment of physiological or drug-induced psychosis or dyskinesia in a mammal. These novel compounds are selective sigma receptor antagonists and have a low potential for movement disorder side effects associated with typical antipsychotic agents.

Treatment of psychosis using 1-cycloalkylpiperidines

Antipsychotic 1-cycloalkylpiperidines

Growing community of inventors

Wilmington, DE, United States of America

Gary Avonn Cain